Stains
BRAF


Topic Completed: 1 January 2012

Revised: 4 March 2019

Copyright: 2003-2018, PathologyOutlines.com, Inc.

PubMed Search: BRAF[title]

Nat Pernick, M.D.
Page views in 2018: 2,605
Page views in 2019 to date: 2,650
Cite this page: Pernick N. BRAF. PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/stainsbraf.html. Accessed September 23rd, 2019.
Definition / general
  • Serine / threonine specific protein kinase, part of the RAS / MAPK pathway regulating the growth, maturation, proliferation, survival and apoptosis of cells
  • Abbreviation for v-raf murine sarcoma viral oncogene homolog B1
  • Gene commonly mutated in papillary thyroid carcinoma and melanoma
  • V600E mutation (valine at residue 600 replaced by glutamic acid) renders BRAF constitutively active and increases its kinase activity (Nature 2002;417:949)
Diagrams / tables
Images hosted on other servers:

MAPK signaling pathway

Clinical features
  • The drug Vemurafenib / Zelboraf®, used to treat melanoma, interrupts the BRAF / MEK / ERK pathway, only when BRAF has the V600E mutation (valine replaced by glutamic acid)
Uses by pathologists
Microscopic (histologic) images
Images hosted on PathOut server:

Courtesy of Andrey Bychkov, M.D., Ph.D.

V600E mutant protein is diffusely expresed in tumor / cancer, but not normal tissue

Diffuse cytoplasmic staining



Images hosted on other servers:
   

Prevalence of BRAF mutations
in different histologic variants
of thyroid papillary carcinoma

Negative stains
Molecular / cytogenetics description
Molecular / cytogenetics images
Images hosted on other servers:

BRAF melting curves

Back to top